606 reports of this reaction
2.0% of all ATOMOXETINE reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for ATOMOXETINE, manufactured by Aurobindo Pharma Limited. There are 606 FDA adverse event reports linking ATOMOXETINE to OFF LABEL USE. This represents approximately 2.0% of all 30,444 adverse event reports for this drug.
Patients taking ATOMOXETINE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for ATOMOXETINE, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for ATOMOXETINE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 606 FDA reports for ATOMOXETINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.0% of all adverse event reports for ATOMOXETINE, making it one of the most commonly reported side effect.
If you experience off label use while taking ATOMOXETINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.